TW200911803A - 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives - Google Patents

6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives Download PDF

Info

Publication number: TW200911803A
Authority: TW; Taiwan
Prior art keywords: phenyl; imidazo; pyridine; methyl; carbonitrile
Prior art date: 2007-07-16

Application number

TW097122685A

Other languages

English (en)

Chinese (zh)

Inventor

Jia-Qiang Cai

Zoran Rankovic

Philip Stephen Jones

David Jonathan Bennett

Xavier Fradera

Original Assignee

Organon Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-16

Filing date

2008-06-18

Publication date

2009-03-16

2008-06-18 Application filed by Organon Nv filed Critical Organon Nv

2009-03-16 Publication of TW200911803A publication Critical patent/TW200911803A/zh

Links

PWCCDWCZFKPZBK-UHFFFAOYSA-N 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile Chemical class C=1C=2NC=NC=2C(C#N)=NC=1C1=CC=CC=C1 PWCCDWCZFKPZBK-UHFFFAOYSA-N 0.000 title claims description 12
208000002193 Pain Diseases 0.000 claims abstract description 8
201000004681 Psoriasis Diseases 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 8
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 8
206010061218 Inflammation Diseases 0.000 claims abstract description 6
239000003814 drug Substances 0.000 claims abstract description 6
230000004054 inflammatory process Effects 0.000 claims abstract description 6
208000000094 Chronic Pain Diseases 0.000 claims abstract description 5
208000026278 immune system disease Diseases 0.000 claims abstract description 5
208000004296 neuralgia Diseases 0.000 claims abstract description 4
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
-1 N-Methylaminocarbonyl Chemical group 0.000 claims description 82
GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 claims description 64
125000000217 alkyl group Chemical group 0.000 claims description 46
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 37
150000003839 salts Chemical class 0.000 claims description 24
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
125000005842 heteroatom Chemical group 0.000 claims description 20
229910052757 nitrogen Inorganic materials 0.000 claims description 19
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
125000000623 heterocyclic group Chemical group 0.000 claims description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
229910052736 halogen Inorganic materials 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
206010003210 Arteriosclerosis Diseases 0.000 claims description 8
208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
QKEOPKYYNVLLLF-UHFFFAOYSA-N pyridin-1-ium-4-carbonitrile chloride Chemical compound [Cl-].N#CC1=CC=[NH+]C=C1 QKEOPKYYNVLLLF-UHFFFAOYSA-N 0.000 claims description 8
208000001132 Osteoporosis Diseases 0.000 claims description 7
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 7
229910052707 ruthenium Inorganic materials 0.000 claims description 7
WQQPZHMVRHAQLD-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridine-4-carbonitrile Chemical compound N#CC1=NC=CC2=C1N=CN2 WQQPZHMVRHAQLD-UHFFFAOYSA-N 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 6
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
239000007789 gas Substances 0.000 claims description 6
GPHQHTOMRSGBNZ-HOSYLAQJSA-N pyridine-4-carbonitrile Chemical class N#[13C]C1=CC=NC=C1 GPHQHTOMRSGBNZ-HOSYLAQJSA-N 0.000 claims description 6
229910052717 sulfur Inorganic materials 0.000 claims description 6
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
125000000753 cycloalkyl group Chemical group 0.000 claims description 5
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 5
125000000468 ketone group Chemical group 0.000 claims description 5
229930194542 Keto Natural products 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 4
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
239000002671 adjuvant Substances 0.000 claims description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
229910052747 lanthanoid Inorganic materials 0.000 claims description 3
150000002602 lanthanoids Chemical class 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
150000001335 aliphatic alkanes Chemical group 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 2
229920006395 saturated elastomer Polymers 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims 2
235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
235000011613 Pinus brutia Nutrition 0.000 claims 1
241000018646 Pinus brutia Species 0.000 claims 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
108090000613 Cathepsin S Proteins 0.000 abstract description 17
102100035654 Cathepsin S Human genes 0.000 abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
201000010099 disease Diseases 0.000 abstract description 9
208000008589 Obesity Diseases 0.000 abstract description 4
235000020824 obesity Nutrition 0.000 abstract description 4
201000001320 Atherosclerosis Diseases 0.000 abstract description 3
206010058019 Cancer Pain Diseases 0.000 abstract 1
208000021722 neuropathic pain Diseases 0.000 abstract 1
238000005481 NMR spectroscopy Methods 0.000 description 143
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 121
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 107
239000000203 mixture Substances 0.000 description 81
150000001875 compounds Chemical class 0.000 description 80
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 76
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 53
235000019439 ethyl acetate Nutrition 0.000 description 39
238000000034 method Methods 0.000 description 39
239000000243 solution Substances 0.000 description 34
239000002904 solvent Substances 0.000 description 34
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 29
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
239000000047 product Substances 0.000 description 28
230000002829 reductive effect Effects 0.000 description 28
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
239000012044 organic layer Substances 0.000 description 23
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 19
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
239000002585 base Substances 0.000 description 19
101150041968 CDC13 gene Proteins 0.000 description 18
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
229910052938 sodium sulfate Inorganic materials 0.000 description 18
235000011152 sodium sulphate Nutrition 0.000 description 18
238000004128 high performance liquid chromatography Methods 0.000 description 17
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
239000012458 free base Substances 0.000 description 15
230000000694 effects Effects 0.000 description 14
238000003756 stirring Methods 0.000 description 14
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
229910000027 potassium carbonate Inorganic materials 0.000 description 12
238000005160 1H NMR spectroscopy Methods 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
239000002253 acid Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 10
239000003112 inhibitor Substances 0.000 description 10
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 10
102000005600 Cathepsins Human genes 0.000 description 9
108010084457 Cathepsins Proteins 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
239000012131 assay buffer Substances 0.000 description 9
239000003480 eluent Substances 0.000 description 9
238000001914 filtration Methods 0.000 description 9
150000003840 hydrochlorides Chemical class 0.000 description 9
LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 8
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
150000001412 amines Chemical class 0.000 description 8
239000010949 copper Substances 0.000 description 8
125000004093 cyano group Chemical group *C#N 0.000 description 8
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 8
229910052739 hydrogen Inorganic materials 0.000 description 8
239000000543 intermediate Substances 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
239000007787 solid Substances 0.000 description 8
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 7
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 7
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000012299 nitrogen atmosphere Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
239000000725 suspension Substances 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
102000004171 Cathepsin K Human genes 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
150000001642 boronic acid derivatives Chemical class 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
229940098779 methanesulfonic acid Drugs 0.000 description 6
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 5
108090000625 Cathepsin K Proteins 0.000 description 5
102000035195 Peptidases Human genes 0.000 description 5
108091005804 Peptidases Proteins 0.000 description 5
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
238000006069 Suzuki reaction reaction Methods 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
239000012043 crude product Substances 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
230000036039 immunity Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
229910052700 potassium Inorganic materials 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000012799 strong cation exchange Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
125000005942 tetrahydropyridyl group Chemical group 0.000 description 5
WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
PDPGERGWEOJVDC-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)phenol Chemical compound OC1=CC=C(Br)C=C1C(F)(F)F PDPGERGWEOJVDC-UHFFFAOYSA-N 0.000 description 4
241000208340 Araliaceae Species 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
235000003140 Panax quinquefolius Nutrition 0.000 description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
239000004365 Protease Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
150000001298 alcohols Chemical class 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
125000004494 ethyl ester group Chemical group 0.000 description 4
235000008434 ginseng Nutrition 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
238000002953 preparative HPLC Methods 0.000 description 4
150000003141 primary amines Chemical class 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000007858 starting material Substances 0.000 description 4
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 4
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 3
HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 3
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
229940122805 Cathepsin S inhibitor Drugs 0.000 description 3
102000005927 Cysteine Proteases Human genes 0.000 description 3
108010005843 Cysteine Proteases Proteins 0.000 description 3
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
108010067372 Pancreatic elastase Proteins 0.000 description 3
102000016387 Pancreatic elastase Human genes 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
239000012267 brine Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000007865 diluting Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
102000049698 human CTSK Human genes 0.000 description 3
239000010410 layer Substances 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
210000003712 lysosome Anatomy 0.000 description 3
230000001868 lysosomic effect Effects 0.000 description 3
229960005181 morphine Drugs 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
150000003335 secondary amines Chemical class 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000012265 solid product Substances 0.000 description 3
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
ADXBXIQTAQOYRW-UHFFFAOYSA-N tert-butyl 2,2-dimethyl-3-oxopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)C1(C)C ADXBXIQTAQOYRW-UHFFFAOYSA-N 0.000 description 3
LRYRQGKGCIUVON-UHFFFAOYSA-N tert-butyl 4-(3-hydroxypropyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCCO)CC1 LRYRQGKGCIUVON-UHFFFAOYSA-N 0.000 description 3
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000005406 washing Methods 0.000 description 3
DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
JZUVNIKDGCTGJB-UHFFFAOYSA-N 2-[4-(4-cyano-1-methylimidazo[4,5-c]pyridin-6-yl)-2-(trifluoromethyl)phenoxy]ethyl methanesulfonate Chemical compound C1=C2N(C)C=NC2=C(C#N)N=C1C1=CC=C(OCCOS(C)(=O)=O)C(C(F)(F)F)=C1 JZUVNIKDGCTGJB-UHFFFAOYSA-N 0.000 description 2
VJMBNYVOGLXGPM-UHFFFAOYSA-N 2-[4-bromo-2-(trifluoromethyl)phenoxy]ethanol Chemical compound OCCOC1=CC=C(Br)C=C1C(F)(F)F VJMBNYVOGLXGPM-UHFFFAOYSA-N 0.000 description 2
LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
XUBSFVKMJSBIBH-UHFFFAOYSA-N 3-[4-chloro-2-(trifluoromethyl)phenyl]propan-1-ol Chemical compound OCCCC1=CC=C(Cl)C=C1C(F)(F)F XUBSFVKMJSBIBH-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
KAYQVFYDILZZJH-UHFFFAOYSA-N 4-amino-6-chloro-3-nitropyridine-2-carbonitrile Chemical compound NC1=CC(Cl)=NC(C#N)=C1[N+]([O-])=O KAYQVFYDILZZJH-UHFFFAOYSA-N 0.000 description 2
GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 2
BKUOCVXPMUEPRJ-UHFFFAOYSA-N 6-[4-hydroxy-3-(trifluoromethyl)phenyl]-1-methylimidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1=C2N(C)C=NC2=C(C#N)N=C1C1=CC=C(O)C(C(F)(F)F)=C1 BKUOCVXPMUEPRJ-UHFFFAOYSA-N 0.000 description 2
LQHKBWMDRJSRJZ-UHFFFAOYSA-N 6-chloro-1-methylimidazo[4,5-c]pyridine-4-carbonitrile Chemical compound N1=C(Cl)C=C2N(C)C=NC2=C1C#N LQHKBWMDRJSRJZ-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
239000005662 Paraffin oil Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
MKBBYTQKCOYPMZ-UHFFFAOYSA-N [4-(2-hydroxyethoxy)-3-(trifluoromethyl)phenyl]boronic acid Chemical compound OCCOC1=CC=C(B(O)O)C=C1C(F)(F)F MKBBYTQKCOYPMZ-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical class NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 2
239000000427 antigen Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
238000013211 curve analysis Methods 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000005284 excitation Effects 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001786 isothiazolyl group Chemical group 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000002132 lysosomal effect Effects 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
239000000178 monomer Substances 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
150000002905 orthoesters Chemical class 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
125000001715 oxadiazolyl group Chemical group 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
150000002989 phenols Chemical class 0.000 description 2
150000004885 piperazines Chemical class 0.000 description 2
239000011591 potassium Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
229910000160 potassium phosphate Inorganic materials 0.000 description 2
235000011009 potassium phosphates Nutrition 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
125000003003 spiro group Chemical group 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
239000013638 trimer Substances 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
235000019798 tripotassium phosphate Nutrition 0.000 description 2
IYLGZMTXKJYONK-ACLXAEORSA-N (12s,15r)-15-hydroxy-11,16-dioxo-15,20-dihydrosenecionan-12-yl acetate Chemical compound O1C(=O)[C@](CC)(O)C[C@@H](C)[C@](C)(OC(C)=O)C(=O)OCC2=CCN3[C@H]2[C@H]1CC3 IYLGZMTXKJYONK-ACLXAEORSA-N 0.000 description 1
RFAPOGMFZTYBEW-UHFFFAOYSA-N 1,2,2-trimethylpiperazine Chemical compound CN1CCNCC1(C)C RFAPOGMFZTYBEW-UHFFFAOYSA-N 0.000 description 1
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
OHYXNIKBVJOPQH-UHFFFAOYSA-N 1-methyl-6-[4-(pyrimidin-2-ylmethoxy)-3-(trifluoromethyl)phenyl]imidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1=C2N(C)C=NC2=C(C#N)N=C1C(C=C1C(F)(F)F)=CC=C1OCC1=NC=CC=N1 OHYXNIKBVJOPQH-UHFFFAOYSA-N 0.000 description 1
QNWYDPKLVXAQGO-UHFFFAOYSA-N 1-methyl-6-[4-[(3-propan-2-yl-1,2,4-oxadiazol-5-yl)methoxy]-3-(trifluoromethyl)phenyl]imidazo[4,5-c]pyridine-4-carbonitrile Chemical compound CC(C)C1=NOC(COC=2C(=CC(=CC=2)C=2N=C(C=3N=CN(C)C=3C=2)C#N)C(F)(F)F)=N1 QNWYDPKLVXAQGO-UHFFFAOYSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
XGMDYIYCKWMWLY-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonic acid Chemical compound OS(=O)(=O)CC(F)(F)F XGMDYIYCKWMWLY-UHFFFAOYSA-N 0.000 description 1
ONOBXDPYDHTSBQ-UHFFFAOYSA-N 2,3,4,7-tetrahydro-1h-diazepine Chemical compound C1CC=CCNN1 ONOBXDPYDHTSBQ-UHFFFAOYSA-N 0.000 description 1
KJVKGYRFRFXCQQ-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridin-4-amine Chemical compound NC1=CC(Cl)=NC(Cl)=C1[N+]([O-])=O KJVKGYRFRFXCQQ-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
IOCQOVHGKQQIHI-UHFFFAOYSA-N 2-[2-[4-bromo-2-(trifluoromethyl)phenoxy]ethoxy]oxane Chemical compound FC(F)(F)C1=CC(Br)=CC=C1OCCOC1OCCCC1 IOCQOVHGKQQIHI-UHFFFAOYSA-N 0.000 description 1
BXZYZNYJSOOGIO-UHFFFAOYSA-N 2-[3-[4-bromo-2-(trifluoromethyl)phenoxy]propoxy]oxane Chemical compound FC(F)(F)C1=CC(Br)=CC=C1OCCCOC1OCCCC1 BXZYZNYJSOOGIO-UHFFFAOYSA-N 0.000 description 1
YKWBEPUOVBMENG-UHFFFAOYSA-N 2-chloro-5-nitropyridin-4-amine Chemical compound NC1=CC(Cl)=NC=C1[N+]([O-])=O YKWBEPUOVBMENG-UHFFFAOYSA-N 0.000 description 1
CDODDZJCEADUQQ-UHFFFAOYSA-N 3,3-dimethylpiperidine Chemical compound CC1(C)CCCNC1 CDODDZJCEADUQQ-UHFFFAOYSA-N 0.000 description 1
SGEKXJLVCMTVFD-UHFFFAOYSA-N 3,4-diamino-6-chloropyridine-2-carbonitrile Chemical compound NC1=CC(Cl)=NC(C#N)=C1N SGEKXJLVCMTVFD-UHFFFAOYSA-N 0.000 description 1
YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 1
CKSHJPUXJCBREM-UHFFFAOYSA-N 3-[4-bromo-2-(trifluoromethyl)phenoxy]propan-1-ol Chemical compound OCCCOC1=CC=C(Br)C=C1C(F)(F)F CKSHJPUXJCBREM-UHFFFAOYSA-N 0.000 description 1
XIZOPJUMQDTYRX-UHFFFAOYSA-N 3-amino-6-chloro-4-(methylamino)pyridine-2-carbonitrile Chemical compound CNC1=CC(Cl)=NC(C#N)=C1N XIZOPJUMQDTYRX-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
CQVWOJSAGPFDQL-UHFFFAOYSA-N 3-iodopropan-1-ol Chemical compound OCCCI CQVWOJSAGPFDQL-UHFFFAOYSA-N 0.000 description 1
MEHWOCVPNCEIJO-UHFFFAOYSA-N 3-methyl-2,2-di(propan-2-yl)butan-1-amine Chemical compound CC(C)C(CN)(C(C)C)C(C)C MEHWOCVPNCEIJO-UHFFFAOYSA-N 0.000 description 1
VIIIJFZJKFXOGG-UHFFFAOYSA-N 3-methylchromen-2-one Chemical compound C1=CC=C2OC(=O)C(C)=CC2=C1 VIIIJFZJKFXOGG-UHFFFAOYSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
USEOPNPHQZGLCS-UHFFFAOYSA-N 4-(3-bromopropyl)piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCN(CCCBr)CC1 USEOPNPHQZGLCS-UHFFFAOYSA-N 0.000 description 1
MRINWLDDTZFLSW-UHFFFAOYSA-N 4-aminopyrimidine-2-carbonitrile Chemical class NC1=CC=NC(C#N)=N1 MRINWLDDTZFLSW-UHFFFAOYSA-N 0.000 description 1
ITACEYFYAGBACM-UHFFFAOYSA-N 4-bromo-1-(2-methoxyethoxymethoxy)-2-(trifluoromethyl)benzene Chemical compound COCCOCOC1=CC=C(Br)C=C1C(F)(F)F ITACEYFYAGBACM-UHFFFAOYSA-N 0.000 description 1
JXHWAPDBDXPBEQ-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)benzoic acid Chemical group OC(=O)C1=CC=C(Br)C=C1C(F)(F)F JXHWAPDBDXPBEQ-UHFFFAOYSA-N 0.000 description 1
GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical class OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
DRMQJFVDZWIKTE-UHFFFAOYSA-N 4-chloro-1-iodo-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(Cl)=CC=C1I DRMQJFVDZWIKTE-UHFFFAOYSA-N 0.000 description 1
KMUGJWJNIUJVMF-UHFFFAOYSA-N 4-oxo-3H-pyridine-2-carbonitrile Chemical compound C(#N)C1=NC=CC(C1)=O KMUGJWJNIUJVMF-UHFFFAOYSA-N 0.000 description 1
IAKQYJGYZJGWLB-UHFFFAOYSA-N 6,9-diazaspiro[4.5]decane Chemical compound C1CCCC21NCCNC2 IAKQYJGYZJGWLB-UHFFFAOYSA-N 0.000 description 1
DXSGNKYVWDGHOR-UHFFFAOYSA-N 6,9-diazaspiro[4.5]decane;dihydrochloride Chemical compound Cl.Cl.C1CCCC21NCCNC2 DXSGNKYVWDGHOR-UHFFFAOYSA-N 0.000 description 1
OTMMFTMARUWKGF-UHFFFAOYSA-N 6-[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]-1-methylimidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1=C2N(C)C=NC2=C(C#N)N=C1C1=CC(Cl)=C(O)C(C(F)(F)F)=C1 OTMMFTMARUWKGF-UHFFFAOYSA-N 0.000 description 1
COODJZOSFKXJEK-UHFFFAOYSA-N 6-[4-(2-hydroxyethoxy)-3-(trifluoromethyl)phenyl]-1-methylimidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1=C2N(C)C=NC2=C(C#N)N=C1C1=CC=C(OCCO)C(C(F)(F)F)=C1 COODJZOSFKXJEK-UHFFFAOYSA-N 0.000 description 1
WRQRIRSTCNECFP-UHFFFAOYSA-N 6-[4-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy]-3-(trifluoromethyl)phenyl]-1-methylimidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1=C2N(C)C=NC2=C(C#N)N=C1C(C=C1C(F)(F)F)=CC=C1OCCN1CCN(CCO)CC1 WRQRIRSTCNECFP-UHFFFAOYSA-N 0.000 description 1
JJIXJXBRCRZXIT-IYBDPMFKSA-N 6-[4-[3-[(3r,5s)-3,5-dimethylpiperazin-1-yl]propoxy]-3-(trifluoromethyl)phenyl]-1-methylimidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCOC1=CC=C(C=2N=C(C=3N=CN(C)C=3C=2)C#N)C=C1C(F)(F)F JJIXJXBRCRZXIT-IYBDPMFKSA-N 0.000 description 1
KLYISVKRJGPHKC-UHFFFAOYSA-N 6-[4-[3-[4-(2-methoxyethyl)piperazin-1-yl]propyl]-3-(trifluoromethyl)phenyl]-1-methylimidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1CN(CCOC)CCN1CCCC1=CC=C(C=2N=C(C=3N=CN(C)C=3C=2)C#N)C=C1C(F)(F)F KLYISVKRJGPHKC-UHFFFAOYSA-N 0.000 description 1
BRFWQRVXVCDZJL-UHFFFAOYSA-N 6-chloro-1-(oxan-2-yl)imidazo[4,5-c]pyridine-4-carbonitrile Chemical compound C1=NC=2C(C#N)=NC(Cl)=CC=2N1C1CCCCO1 BRFWQRVXVCDZJL-UHFFFAOYSA-N 0.000 description 1
ZDENKPYKHHGLOM-UHFFFAOYSA-N 6-chloro-1h-imidazo[4,5-c]pyridine-4-carbonitrile Chemical compound N#CC1=NC(Cl)=CC2=C1N=CN2 ZDENKPYKHHGLOM-UHFFFAOYSA-N 0.000 description 1
CPPJTEVGUHCBOT-UHFFFAOYSA-N 6-chloro-4-(methylamino)-3-nitropyridine-2-carbonitrile Chemical compound CNC1=CC(Cl)=NC(C#N)=C1[N+]([O-])=O CPPJTEVGUHCBOT-UHFFFAOYSA-N 0.000 description 1
ONYNOPPOVKYGRS-UHFFFAOYSA-N 6-methylindole Natural products CC1=CC=C2C=CNC2=C1 ONYNOPPOVKYGRS-UHFFFAOYSA-N 0.000 description 1
WPSLKEHAOKNPSH-UHFFFAOYSA-N 6-phenyl-3h-imidazo[4,5-c]pyridine Chemical class C1=C2NC=NC2=CN=C1C1=CC=CC=C1 WPSLKEHAOKNPSH-UHFFFAOYSA-N 0.000 description 1
CFNMUZCFSDMZPQ-GHXNOFRVSA-N 7-[(z)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]chromen-2-one Chemical compound C=1C=C2C=CC(=O)OC2=CC=1OC/C=C(/C)CC1OC(=O)C(C)=C1 CFNMUZCFSDMZPQ-GHXNOFRVSA-N 0.000 description 1
KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
UCDBLYHPJMMFMY-UHFFFAOYSA-N 8-bromoquinoline-4-carbonitrile Chemical compound C1=CN=C2C(Br)=CC=CC2=C1C#N UCDBLYHPJMMFMY-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
KBCGSUDSGWQTKT-UHFFFAOYSA-N CCCCCCCCCNC1=CC2=C(C=C1)C=CC(=O)O2 Chemical class CCCCCCCCCNC1=CC2=C(C=C1)C=CC(=O)O2 KBCGSUDSGWQTKT-UHFFFAOYSA-N 0.000 description 1
108090000712 Cathepsin B Proteins 0.000 description 1
102000004225 Cathepsin B Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ILMSWNSHYMHTJG-UHFFFAOYSA-N Cl.N#Cc1nccc2[nH]cnc12 Chemical compound Cl.N#Cc1nccc2[nH]cnc12 ILMSWNSHYMHTJG-UHFFFAOYSA-N 0.000 description 1
101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 1
101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010011084 Coronary artery embolism Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
229940094664 Cysteine protease inhibitor Drugs 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
238000007341 Heck reaction Methods 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
229920000877 Melamine resin Polymers 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
244000294411 Mirabilis expansa Species 0.000 description 1
235000015429 Mirabilis expansa Nutrition 0.000 description 1
238000006751 Mitsunobu reaction Methods 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
238000007126 N-alkylation reaction Methods 0.000 description 1
BJXJYBUBFHYNSM-UHFFFAOYSA-L O.O.[Sn](Cl)Cl.NC=1C(=NC(=CC1NC)Cl)C#N Chemical compound O.O.[Sn](Cl)Cl.NC=1C(=NC(=CC1NC)Cl)C#N BJXJYBUBFHYNSM-UHFFFAOYSA-L 0.000 description 1
108010077077 Osteonectin Proteins 0.000 description 1
102000009890 Osteonectin Human genes 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
241000239226 Scorpiones Species 0.000 description 1
229920002472 Starch Chemical class 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
QOVRQYBHDTTXQD-UHFFFAOYSA-N [4-(2-methoxyethoxymethoxy)-3-(trifluoromethyl)phenyl]boronic acid Chemical compound COCCOCOC1=CC=C(B(O)O)C=C1C(F)(F)F QOVRQYBHDTTXQD-UHFFFAOYSA-N 0.000 description 1
DWQZTGOVVPANIB-UHFFFAOYSA-N [4-(3-hydroxypropoxy)-3-(trifluoromethyl)phenyl]boronic acid Chemical compound OCCCOC1=CC=C(B(O)O)C=C1C(F)(F)F DWQZTGOVVPANIB-UHFFFAOYSA-N 0.000 description 1
KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
VKLUVISTQXQYPF-UHFFFAOYSA-N aminoazanium trifluoromethanesulfonate Chemical compound [NH3+]N.[O-]S(=O)(=O)C(F)(F)F VKLUVISTQXQYPF-UHFFFAOYSA-N 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
VCOVUYXJMHMVNV-FMYROPPKSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 VCOVUYXJMHMVNV-FMYROPPKSA-N 0.000 description 1
108010085937 benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
125000006267 biphenyl group Chemical group 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
238000007333 cyanation reaction Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000006837 decompression Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
HDULBKVLSJEMGN-UHFFFAOYSA-N dicyclohexylphosphane Chemical compound C1CCCCC1PC1CCCCC1 HDULBKVLSJEMGN-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
239000005457 ice water Substances 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
229960002182 imipenem Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
108010028930 invariant chain Proteins 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
238000006138 lithiation reaction Methods 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
238000011068 loading method Methods 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
PKAUVIXBZJUYRV-UHFFFAOYSA-N methane;hydroiodide Chemical compound C.I PKAUVIXBZJUYRV-UHFFFAOYSA-N 0.000 description 1
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
YVMDZGNUXHZQNE-UHFFFAOYSA-N methyl 3-[4-chloro-2-(trifluoromethyl)phenyl]propanoate Chemical compound COC(=O)CCC1=CC=C(Cl)C=C1C(F)(F)F YVMDZGNUXHZQNE-UHFFFAOYSA-N 0.000 description 1
229940017219 methyl propionate Drugs 0.000 description 1
CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
235000013536 miso Nutrition 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
RAERXUHIYOISPV-UHFFFAOYSA-N phenoxy methanesulfonate Chemical compound O(C1=CC=CC=C1)OS(=O)(=O)C RAERXUHIYOISPV-UHFFFAOYSA-N 0.000 description 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
239000001294 propane Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
108010043535 protease S Proteins 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
OLDDTCAJGHYZEX-UHFFFAOYSA-N pyrene-4-carbonitrile Chemical compound C1=CC=C2C(C#N)=CC3=CC=CC4=CC=C1C2=C34 OLDDTCAJGHYZEX-UHFFFAOYSA-N 0.000 description 1
OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
238000010791 quenching Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
IYLGZMTXKJYONK-UHFFFAOYSA-N ruwenine Natural products O1C(=O)C(CC)(O)CC(C)C(C)(OC(C)=O)C(=O)OCC2=CCN3C2C1CC3 IYLGZMTXKJYONK-UHFFFAOYSA-N 0.000 description 1
239000004576 sand Substances 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Chemical class 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000013517 stratification Methods 0.000 description 1
239000012607 strong cation exchange resin Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
YBNJZIDYXCGAPX-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)CC1 YBNJZIDYXCGAPX-UHFFFAOYSA-N 0.000 description 1
SQJTVQSZFVOIQV-UHFFFAOYSA-N tert-butyl 4-(3-bromopropyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCCBr)CC1 SQJTVQSZFVOIQV-UHFFFAOYSA-N 0.000 description 1
JWZSWVHWKOPPNT-UHFFFAOYSA-N tert-butyl 4-[3-[2-chloro-4-(4-cyano-1-methylimidazo[4,5-c]pyridin-6-yl)-6-(trifluoromethyl)phenoxy]propyl]piperazine-1-carboxylate Chemical compound C1=C2N(C)C=NC2=C(C#N)N=C1C(C=C1C(F)(F)F)=CC(Cl)=C1OCCCN1CCN(C(=O)OC(C)(C)C)CC1 JWZSWVHWKOPPNT-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
230000009466 transformation Effects 0.000 description 1
AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TW097122685A 2007-07-16 2008-06-18 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives TW200911803A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP07112517		2007-07-16

Publications (1)

Publication Number	Publication Date
TW200911803A true TW200911803A (en)	2009-03-16

Family

ID=38846911

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW097122685A TW200911803A (en)	2007-07-16	2008-06-18	6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives

Country Status (19)

Country	Link
EP (1)	EP2178873B1 (pt)
JP (1)	JP5371976B2 (pt)
KR (1)	KR20100043235A (pt)
CN (1)	CN101842373B (pt)
AR (1)	AR067530A1 (pt)
AT (1)	ATE492546T1 (pt)
AU (1)	AU2008277679B2 (pt)
BR (1)	BRPI0813587A2 (pt)
CA (1)	CA2693887A1 (pt)
CL (1)	CL2008002082A1 (pt)
DE (1)	DE602008004167D1 (pt)
EC (1)	ECSP109966A (pt)
ES (1)	ES2356279T3 (pt)
IL (1)	IL202769A0 (pt)
PE (1)	PE20091087A1 (pt)
RU (1)	RU2485119C2 (pt)
TW (1)	TW200911803A (pt)
WO (1)	WO2009010491A1 (pt)
ZA (1)	ZA200909132B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7932251B2 (en)	2007-07-16	2011-04-26	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) *	2009-01-16	2010-10-01	Organon Nv	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8026236B2 (en)	2009-01-16	2011-09-27	N.V. Organon	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2523954B1 (en)	2010-01-15	2014-04-16	Merck Sharp & Dohme B.V.	1h-[1,2,3]triazolo[4,5-c]pyridine-4- carbonitrile derivatives as cathepsin s inhibitors
EP2727920B1 (en)	2011-07-29	2016-11-02	FUJIFILM Corporation	1,5-naphthyridine derivative or salt thereof
CA2870527A1 (en) *	2012-04-17	2013-10-24	Astellas Pharma Inc.	Nitrogenated bicyclic aromatic heterocyclic compound
EP3887376A1 (en)	2018-11-28	2021-10-06	Topadur Pharma AG	Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
AU2020250933A1 (en)	2019-04-05	2021-10-28	Centre Hospitalier Régional Et Universitaire De Brest	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CA3168146A1 (en)	2020-01-20	2021-07-29	Genzyme Corporation	Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
EP3858471A1 (en)	2020-01-31	2021-08-04	Novamem AG	Solvent-free production of porous polymer structures
CA3201936A1 (en)	2020-12-10	2022-06-16	Minhua Chen	Crystal form of tolebrutinib and preparation method thereof
IL303834A (en)	2020-12-23	2023-08-01	Genzyme Corp	4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA62972C2 (en) *	1997-07-03	2004-01-15		Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
GB9921150D0 (en) *	1999-09-07	1999-11-10	Merck Sharp & Dohme	Therapeutic agents
PA8535601A1 (es) *	2000-12-21	2002-11-28	Pfizer	Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0121033D0 (en) *	2001-08-30	2001-10-24	Novartis Ag	Organic compounds
SE0201980D0 (sv) *	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
FR2852957B1 (fr) *	2003-03-31	2005-06-10	Sod Conseils Rech Applic	Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
EP1724264A1 (en) *	2004-03-10	2006-11-22	Ono Pharmaceutical Co., Ltd.	Nitriles and medicinal compositions containing the same as the active ingredient
TW200734338A (en) *	2006-01-16	2007-09-16	Organon Nv	6-Phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives

2008
- 2008-06-18 TW TW097122685A patent/TW200911803A/zh unknown
- 2008-07-14 AU AU2008277679A patent/AU2008277679B2/en not_active Ceased
- 2008-07-14 CA CA2693887A patent/CA2693887A1/en not_active Abandoned
- 2008-07-14 PE PE2008001179A patent/PE20091087A1/es not_active Application Discontinuation
- 2008-07-14 WO PCT/EP2008/059172 patent/WO2009010491A1/en not_active Ceased
- 2008-07-14 BR BRPI0813587-8A2A patent/BRPI0813587A2/pt not_active Application Discontinuation
- 2008-07-14 DE DE602008004167T patent/DE602008004167D1/de active Active
- 2008-07-14 JP JP2010516481A patent/JP5371976B2/ja not_active Expired - Fee Related
- 2008-07-14 EP EP08786128A patent/EP2178873B1/en active Active
- 2008-07-14 ES ES08786128T patent/ES2356279T3/es active Active
- 2008-07-14 AR ARP080103015A patent/AR067530A1/es unknown
- 2008-07-14 AT AT08786128T patent/ATE492546T1/de not_active IP Right Cessation
- 2008-07-14 CN CN200880024871XA patent/CN101842373B/zh not_active Expired - Fee Related
- 2008-07-14 RU RU2010105234/04A patent/RU2485119C2/ru not_active IP Right Cessation
- 2008-07-14 KR KR1020107003287A patent/KR20100043235A/ko not_active Withdrawn
- 2008-07-15 CL CL2008002082A patent/CL2008002082A1/es unknown
2009
- 2009-12-16 IL IL202769A patent/IL202769A0/en unknown
- 2009-12-21 ZA ZA200909132A patent/ZA200909132B/xx unknown
2010
- 2010-02-12 EC EC2010009966A patent/ECSP109966A/es unknown

Also Published As

Publication number	Publication date
CA2693887A1 (en)	2009-01-22
PE20091087A1 (es)	2009-07-20
AU2008277679B2 (en)	2012-11-15
AR067530A1 (es)	2009-10-14
RU2010105234A (ru)	2011-08-27
EP2178873B1 (en)	2010-12-22
JP2010533675A (ja)	2010-10-28
BRPI0813587A2 (pt)	2014-12-30
IL202769A0 (en)	2010-06-30
EP2178873A1 (en)	2010-04-28
HK1142323A1 (en)	2010-12-03
JP5371976B2 (ja)	2013-12-18
AU2008277679A1 (en)	2009-01-22
WO2009010491A1 (en)	2009-01-22
RU2485119C2 (ru)	2013-06-20
ATE492546T1 (de)	2011-01-15
CN101842373B (zh)	2013-12-18
DE602008004167D1 (en)	2011-02-03
CL2008002082A1 (es)	2009-01-02
ECSP109966A (es)	2010-03-31
ES2356279T3 (es)	2011-04-06
CN101842373A (zh)	2010-09-22
KR20100043235A (ko)	2010-04-28
ZA200909132B (en)	2010-08-25

Publication	Publication Date	Title
JP7208142B2 (ja)	2023-01-18	Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
JP5371976B2 (ja)	2013-12-18	カテプシン阻害剤としての６−フェニル−１Ｈ−イミダゾ［４，５−ｃ］ピリジン−４−カルボニトリル誘導体
AU2024227155A1 (en)	2024-10-31	Carboxy-benzimidazole GLP-1R modulating compounds.
JP6256467B2 (ja)	2018-01-10	ロイコトリエン生成を阻害するピラゾール誘導体
WO2025029683A1 (en)	2025-02-06	Pi3k inhibitors
US7932251B2 (en)	2011-04-26	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP2004513134A (ja)	2004-04-30	Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類
RS55602B1 (sr)	2017-06-30	Inhibitori kinaza
CN116981675A (zh)	2023-10-31	通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
JP2018505207A (ja)	2018-02-22	置換モノおよびポリアザナフタレン誘導体およびその使用
KR20180135885A (ko)	2018-12-21	브루톤 티로신 키나제 억제제
TW202214233A (zh)	2022-04-16	可做為tlr9抑制劑之經取代雜芳基化合物
JP2010500305A (ja)	2010-01-07	Ｐ３８ｍａｐキナーゼ阻害剤としての１，７−ナフチリジン誘導体
TW202421135A (zh)	2024-06-01	治療癌症之方法
WO2024081889A1 (en)	2024-04-18	4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
EP3807273B1 (en)	2022-08-03	Azaindole derivatives as rho-kinase inhibitors
TW202302585A (zh)	2023-01-16	具有四氫吲哚－１－甲醯胺作為ｂｃｌ－２抑制劑之化合物
JP2016525113A (ja)	2016-08-22	ロイコトリエン生成の阻害剤
EP2387573B1 (en)	2013-07-31	6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile derivatives as cathepsin s and/or cathepsin k inhibitors
JP2023552902A (ja)	2023-12-19	Ｒｈｏ－キナーゼ阻害剤としてのジヒドロフロピリジン誘導体
US8026236B2 (en)	2011-09-27	6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
CN118973578A (zh)	2024-11-15	药物化合物
EP4698517A1 (en)	2026-02-25	<sup2/>? <sub2/>?4?novel compounds as ?? <ns1:sub>7</ns1:sub>?inhibitors
Bhalay	2018	Preparation of tyrosine amide derivatives as Rho- kinase inhibitors
OA18588A (en)	2018-12-28	1,1,1-Trifluoro-3-Hydroxypropan-2-yl Carbamate Derivatives and 1,1,1-Trifluoro-4Hydroxybutan-2-yl Carbamate Derivatives as Magl Inhibitors.